EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY 4.0

Brodalumab Is Effective for Psoriasis Patients with Difficult-To-Treat Body Regions: Results from an Observational Clinical Study

Stephanie Dauth, Ann Christina Foldenauer, Konstantin Hallmann, Christina Kunz, Anke König, Isabel Haferland, Christine Möser, Michaela Koehm, Andreas Pinter

Dermatology · 2024

DOI: 10.1159/000542348 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Dermatology, 2024. Verfasst von Stephanie Dauth und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department for Clinical Research, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany. Hauptthemen laut MEDLINE: Psoriasis, Antibodies, Monoclonal, Humanized, Dermatologic Agents, Antibodies, Monoclonal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Brodalumab, a human monoclonal antibody that selectively inhibits the interleukin (IL)-17 receptor subunit A, has been approved for the treatment of moderate-to-severe plaque psoriasis. The treatment benefit of brodalumab has been clearly demonstrated in multiple clinical studies. However, data on effectiveness for difficult-to-treat body regions, especially in everyday clinical practice, are still limited.

Methods

In this exploratory observational clinical study, psoriasis patients suffering from nail and scalp involvement who received brodalumab during routine clinical care were enrolled at 7 centers in Germany. Patients were observed for over 60 weeks. The co-primary endpoints were 75% improvement in Psoriasis Scalp Severity Index (PSSI75) at week 12 and 75% improvement in Nail Psoriasis Severity Index (NAPSI75) at week 24. Secondary endpoints included assessment of general skin and disease outcomes, quality-of-life, and patient satisfaction with treatment.

Results

Eighty-seven patients were included. Mean age was 46.8 years, 70.1% patients were male, and mean body mass index was 28.9 kg/m2. The co-primary endpoints were achieved by more than 90% of patients who met criteria for effectiveness analyses (n = 62): 93.6% of patients achieved PSSI75 at week 12 and 90.3% of patients achieved NAPSI75 at week 24. Median body surface area involvement improved from 14% at baseline to 1.5% and 1% at weeks 12 and 24, respectively. Median Dermatology Life Quality Index scores improved from 16 at baseline to 2 and 1 at weeks 12 and 24, respectively. Improvements were maintained in the majority of patients throughout the 60-week study. Brodalumab was well tolerated and patients were highly satisfied with the treatment.

Conclusion

Outcomes assessed in this study, including assessments of scalp and nail symptoms, improved following initiation of brodalumab therapy. This study of psoriasis patients in a real-world setting supports the long-term clinical effectiveness of brodalumab on difficult-to-treat body regions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisAntibodies, Monoclonal, HumanizedDermatologic AgentsAntibodies, MonoclonalScalp DermatosesNail DiseasesHumansMaleFemaleMiddle AgedAdultSeverity of Illness IndexTreatment OutcomeQuality of LifePatient SatisfactionAged

Stichwörter der Autor:innen

Difficult-to-treat body regionsIL-17 inhibitionNail psoriasisPlaque psoriasisReal-world settingScalp psoriasis

Substanzen

Antibodies, Monoclonal, HumanizedbrodalumabDermatologic AgentsAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department for Clinical Research, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany.
  • Fraunhofer Cluster of Excellence Immune-Mediated Diseases CIMD, Frankfurt, Germany.
  • Clinic for Dermatology, Venerology, and Allergology, University Hospital Frankfurt, Frankfurt, Germany.
  • Department of Rheumatology, University Hospital Frankfurt, Frankfurt, Germany.

Zitieren

APA

Dauth, S., Foldenauer, A. C., Hallmann, K., Kunz, C., König, A., Haferland, I., Möser, C., Koehm, M., & Pinter, A. (2024). Brodalumab Is Effective for Psoriasis Patients with Difficult-To-Treat Body Regions: Results from an Observational Clinical Study. Dermatology. https://doi.org/10.1159/000542348

Vancouver

Dauth S, Foldenauer AC, Hallmann K, Kunz C, König A, Haferland I, et al. Brodalumab Is Effective for Psoriasis Patients with Difficult-To-Treat Body Regions: Results from an Observational Clinical Study. Dermatology. 2024. doi:10.1159/000542348

BibTeX
@article{Dauth2024,
  author = {Dauth, Stephanie and Foldenauer, Ann Christina and Hallmann, Konstantin and Kunz, Christina and König, Anke and Haferland, Isabel and Möser, Christine and Koehm, Michaela and Pinter, Andreas},
  title = {Brodalumab Is Effective for Psoriasis Patients with Difficult-To-Treat Body Regions: Results from an Observational Clinical Study},
  journal = {Dermatology},
  year = {2024},
  doi = {10.1159/000542348}
}
Kostenlos starten →